← Back to Clinical Trials
Recruiting NCT06275230

NCT06275230 Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06275230
Status Recruiting
Phase
Sponsor China-Japan Friendship Hospital
Condition Chronic Obstructive Pulmonary Disease
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2024-03-20
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 55 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2024-03-20 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to proliferate human lung stem cell in vitro in order to establish a lung organoid derived from patients with COPD. The main question it aims to answer are: * Can human lung stem cell proliferate in vitro. * Can a lung organoid derived from patients with COPD be established. Participants will be sampled during pulmonary bronchoscope for organoid establishment.

Eligibility Criteria

Inclusion Criteria: * 1\. Age under 55, regardless of gender * 2\. Patients with COPD lung disease who are going to undergo bronchoscopic biopsy * 3\. No genetic diseases and other respiratory diseases Exclusion Criteria: * Other conditions determined by the investigators to be unsuitable for inclusion, such as difficult sampling, difficult follow-up, and complicated with other serious diseases

Contact & Investigator

Central Contact

Mingming Deng, MD

✉ isdeng1017@163.com

📞 +8618801336854

Frequently Asked Questions

Who can join the NCT06275230 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06275230 currently recruiting?

Yes, NCT06275230 is actively recruiting participants. Contact the research team at isdeng1017@163.com for enrollment information.

Where is the NCT06275230 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06275230 clinical trial?

NCT06275230 is sponsored by China-Japan Friendship Hospital. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology